Ulixertinib (BVD-523) is a first-in-class and best-in-class small molecule inhibitor of ERK 1/2 that is currently being investigated in multiple cancer clinical trials, both as a single agent and as part of combination therapy. Preclinical studies have demonstrated that inhibition of the ...
Ulixertinib (BVD-523, VRT752271) is a potent and reversible ERK1/ERK2 inhibitor with IC50 of <0.3 nM for ERK2. Phase 1. 体外研究 体内研究 激酶实验 细胞实验 ~30 μM 动物实验 不同实验动物依据体表面积的等效剂量转换表(数据来源于FDA指南) 动物A (mg/kg) = 动物 B (mg/kg)×动物B的Km...
Updated clinical outcomes from ULI-EAP-100, an intermediate expanded access program for ulixertinib (BVD-523).261-566-9263,283-237-267-6887-6888,261-492-2769,283-324,283-237-255,283-232,283-219-418,4,3,2,2,2,2,2,2827,126,1896,81,35,1854,4,3,2,2,1,1,38092-18849,38092-...
BVD-523FB (ulixertinib) is a small molecule that potently inhibits both ERK1 and ERK2 protein kinases in the sub-nanomolar range. Based on the reports of early clinical activity in the phase 1 trial, including in non-V600 BRAF mutations, subprotocol Z1L (EAY131-Z1L) sought to ...